Zobrazeno 1 - 10
of 688
pro vyhledávání: ''
Autor:
Christian Lang, Felix Egger, Mir Alireza Hoda, Alessandro Saeed Querner, Bence Ferencz, Victor Lungu, Robert Szegedi, Levente Bogyo, Klara Torok, Felicitas Oberndorfer, Thomas Klikovits, Anna Schwendenwein, Kristiina Boettiger, Ferenc Renyi-Vamos, Konrad Hoetzenecker, Karin Schelch, Zsolt Megyesfalvi, Balazs Dome
Publikováno v:
Lung Cancer. 169:40-46
The prognostic value of lymphocyte-to-monocyte ratio (LMR) has already been evaluated in a wide range of malignancies including patients with non-surgically managed small cell lung cancer (SCLC). However, the impact of LMR on survival in surgically t
Autor:
Takaaki Tokito, Akihiro Bessho, Satoshi Igawa, Shinji Sasada, Nobuhiko Seki, Naoki Furuya, Yosuke Tanaka, Koichi Minato, Kaoru Kubota, Hideki Hayashi, Hirotoshi Iihara, Rintaro Noro, Takayuki Kaburagi, Tsuneo Shimokawa, Hiroaki Okamoto, Masanao Nakashima, Shingo Miyamoto, T. Hirose, Toshiyuki Harada
Publikováno v:
Lung Cancer. 161:49-54
Objectives Afatinib is an effective treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, the toxicity associated with this agent often leads to dose modifications. The aim
Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)
Publikováno v:
Lung Cancer. 143:40-46
Objectives Little is known regarding the ICPi efficacy in LCNEC. We explored the efficacy and safety of ICPi in LCNEC and assessed its impact on OS. Materials and methods Thirty-seven consecutive patients with advanced LCNEC were selected from the Da
Autor:
Marco Alloisio, Pierluigi Novellis, Giulia Veronesi, Elena Vanni, Niccolò Navone, Michela Solinas, Simone Ghislandi, Luca Toschi, Laura Velutti, Elisa Dieci
Publikováno v:
Lung Cancer. 143:73-79
Objectives: Lung cancer detection by low-dose computed tomographic screening reduces mortality. However, it is essential to assess cost-effectiveness. We present a cost-effectiveness analysis of screening in Italians at high risk of lung cancer, from
Autor:
Anas Gazzah, Pilar Garrido, Alexis B. Cortot, Jaafar Bennouna, Melissa Lynne Johnson, Maciej Gil, Haruyasu Murakami, Benjamin Besse
Publikováno v:
Lung Cancer. 142:63-69
Objectives Efficacy and safety of necitumumab when combined with pembrolizumab was assessed in patients with Stage IV non-small cell lung cancer (NSCLC) of squamous and nonsquamous histology, who had progressed after treatment with a platinum-based d
Autor:
Dhruvin H. Hirpara, Mark Doherty, Alexander V. Louie, Haoyu Zhao, Natalie G. Coburn, Gail Darling, Biniam Kidane, Rinku Sutradhar, Alyson L. Mahar, Julie Hallet, Vaibhav Gupta, Laura E. Davis
Publikováno v:
Lung Cancer. 142:80-89
Objectives Lung cancer is associated with significant disease- and treatment-related morbidity. The Edmonton Symptom Assessment System (ESAS) is a tool developed to elicit patients' own assessment of the severity of common cancer-associated symptoms.
Autor:
Patrick Leo, Pranjal Vaidya, Kaustav Bera, Rajat Thawani, Michael Feldman, Mehdi Alilou, Prabhakar Rajiah, Philip A. Linden, Robert C. Gilkeson, Pingfu Fu, Harvey I. Pass, Mohammadhadi Khorrami, Pradnya D. Patil, Vamsidhar Velcheti, Priya Velu, Humberto Choi, Anant Madabhushi
Publikováno v:
Lung Cancer
Objectives To evaluate whether combining stability and discriminability criteria in building radiomic classifiers will improve the prognosis of cancer recurrence in early stage non-small cell lung cancer on non-contrast computer tomography (CT). Mate
Autor:
Amy T.Y. Chang, Tony Mok, Frankie Mo, Jacky Y.C. Li, Oscar S.H. Chan, Ki Wang, Catherine Y.H. Wong, Rebecca M.W. Yeung, Kwok Chi Lam, Frankie P. T. Choi
Publikováno v:
Lung Cancer. 142:41-46
Objectives NSCLC patients harboring EGFR mutation invariably developed resistance to EGFR TKI. We postulated that oligoresidual disease (ORD) after initial TKI might harbor resistant clones. This study aimed to test if preemptive local ablative thera
Autor:
Kazuya Shinmura, Yuji Iwashita, Masayuki Tanahashi, Kazuhito Funai, Haruhiko Sugimura, Takafumi Suda, Katsuhiro Yoshimura, Naoki Inui, Hiroshi Niwa, Masato Karayama, Hidetaka Yamada, Akikazu Kawase, Yusuke Inoue, Hiroshi Ogawa, Kazuo Tsuchiya
Publikováno v:
Lung Cancer. 141:21-31
Alterations in the MET gene, such as mutations and high-level amplification, are important drivers of non-small cell lung cancer (NSCLC). The efficacy of immune checkpoint inhibitors (ICIs) in lung cancer with MET abnormalities is unclear. We evaluat
Autor:
Michael Millward, Sanjeevan Muruganandan, Wei Sen Lam, J. Spiro, Sukanya Arunachalam, Aron Chakera, Y. C. Gary Lee, Catherine A. Read, Mary S. Attia, Anna K. Nowak, Fred K. Chen, Wee Loong Chin, Kevin Murray, Jenette Creaney
Publikováno v:
Lung Cancer. 140:87-92
Objectives Currently, there is no optimal salvage therapy for patients with malignant pleural mesothelioma (MPM) who relapse after treatment with first-line chemotherapy. In line with the strong preclinical rationale for targeting fibroblast growth f